Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2006 Mar 23;34(6):1685–1691. doi: 10.1093/nar/gkl108

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author 2006. Published by Oxford University Press. All rights reserved

The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org

PMC Copyright notice

Absence of PARP-1 leads to increased sensitivity to ATM inhibition and vice versa. (A) Survival fraction of A19 (WT) and A11 (PARP-1^−/−) MEFs following treatment for 10 days with increasing doses of the ATM inhibitor KU55933. (B) Survival fraction of AT221JE-T/pEBS (pEBS-ATM defective) and pEBS-YZ5 (YZ5—corrected for the AT phenotype by wild-type ATM cDNA) following treatment for 12 days with increasing doses of the PARP inhibitor 4-amino-1,8-napthalamide. The means (symbol) and standard deviations (error bar) from at least three experiments are depicted.